Clinical Trial

Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To prospectively evaluate the efficacy and safety of large fraction radiation therapy combined with granulocyte-macrophage colony-stimulating factor, lenalidomide, and glofitamab monoclonal antibody in the treatment of refractory relapsed diffuse large B-cell lymphoma patients
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-10-19; most recent amendment 2025-07-19.
Trial Details
NCT Number NCT06651853
Lead Sponsor The First Affiliated Hospital of Xiamen University
Conditions Diffuse Large B-cell Lymphoma, Relapsed and Refractory
Enrollment 22 participants
Start Date 2024-10-21
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-07-30 (estimated)
Updated on ClinicalTrials.gov 2025-07-23